Bristol-Myers Squibb Q3 2024 Adj EPS $1.80 Beats $1.49 Estimate, Sales $11.89B Beat $11.28B Estimate
Portfolio Pulse from Benzinga Newsdesk
Bristol-Myers Squibb reported Q3 2024 earnings of $1.80 per share, surpassing the $1.49 estimate, despite a 10% decrease from last year. Sales reached $11.89 billion, exceeding the $11.28 billion estimate and marking an 8.44% increase from the previous year.
October 31, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol-Myers Squibb's Q3 2024 earnings and sales exceeded analyst expectations, with EPS at $1.80 and sales at $11.89 billion. Despite a year-over-year EPS decline, sales increased by 8.44%.
Bristol-Myers Squibb's earnings per share and sales both exceeded analyst expectations, which is typically a positive indicator for stock performance. The EPS beat was significant at 20.81% above estimates, and sales grew by 8.44% year-over-year, suggesting strong operational performance. Despite a 10% decline in EPS from the previous year, the market often reacts positively to earnings beats, especially when both EPS and sales exceed expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100